MCID: KRT006
MIFTS: 53

Keratoconjunctivitis

Categories: Eye diseases, Infectious diseases

Aliases & Classifications for Keratoconjunctivitis

MalaCards integrated aliases for Keratoconjunctivitis:

Name: Keratoconjunctivitis 12 54 43 15 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:9368
ICD9CM 34 370.40
MeSH 43 D007637
NCIt 49 C34744
SNOMED-CT 67 88151007
UMLS 71 C0022573

Summaries for Keratoconjunctivitis

MalaCards based summary : Keratoconjunctivitis is related to vernal keratoconjunctivitis and keratoconjunctivitis sicca. An important gene associated with Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pseudoephedrine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Keratoconjunctivitis is inflammation ("-itis") of the cornea and... more...

Related Diseases for Keratoconjunctivitis

Diseases related to Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 769)
# Related Disease Score Top Affiliating Genes
1 vernal keratoconjunctivitis 34.4 RNASE3 IL5 IL4 IL13 CCL24 CCL11
2 keratoconjunctivitis sicca 34.0 TRIM21 NGF MUC5AC IL4
3 atopic keratoconjunctivitis 33.3 RNASE3 MUC5AC MUC16 IL5 IL4 IL3
4 tropical spastic paraparesis 32.3 MMP9 IL6 IL2 IL17A IFNG
5 dry eye syndrome 32.0 TRIM21 TNF NGF MUC5AC IL6
6 cytokine deficiency 31.3 IL5 IL13
7 keratopathy 31.1 TNF IL4 ICAM1 CXCL8
8 ige responsiveness, atopic 31.1 RNASE3 IL5 IL4 IL13 IFNG
9 vernal conjunctivitis 31.0 RNASE3 IL4 IFNG
10 dysentery 30.9 TNF IL6 CXCL8
11 corneal ulcer 30.9 NGF MUC5AC MMP9 CCL11
12 graft-versus-host disease 30.8 TNF IL6 IL2 IFNG
13 thyroiditis 30.8 TNF IL6 IL4 IL2
14 keratitis, hereditary 30.7 TNF NGF MMP9 IL6 IL17A CXCL8
15 chlamydia pneumonia 30.7 TNF IL6 CXCL8
16 cellulitis 30.7 TNF RNASE3 IL6 IL5
17 papillary conjunctivitis 30.6 IL6 IL4 CXCL8 CCL24 CCL11
18 rosacea 30.6 TNF MMP9 IL6 CXCL8
19 chlamydia 30.6 TNF IL6 IL4 IL17A IFNG CXCL8
20 iridocyclitis 30.5 TNF IL6 IL17A
21 human immunodeficiency virus type 1 30.5 TNF IL6 IL2 IFNG CCL11
22 acquired immunodeficiency syndrome 30.5 TNF IL6 IL2 IFNG ICAM1
23 conjunctivochalasis 30.5 MMP9 IL6 CXCL8
24 alopecia 30.5 TNF IL4 IL2 IFNG
25 trachoma 30.5 TNF IL6 IL4 IL17A
26 pharyngitis 30.5 TNF IL6 CXCL8
27 endophthalmitis 30.4 TNF IL6 ICAM1 CXCL8
28 giant papillary conjunctivitis 30.4 RNASE3 IL6 IL4 CXCL8 CCL24 CCL11
29 multicentric castleman disease 30.4 IL6 IL5 IFNG
30 chickenpox 30.4 TNF IL6 IL4 IL2 IFNG
31 scleritis 30.3 TNF MMP9 IL5 IL4 IFNG
32 blepharoconjunctivitis 30.3 RNASE3 IL4 CXCL8 CCL24 CCL11
33 vaccinia 30.2 TNF IL6 IL2 ICAM1
34 cryoglobulinemia 30.2 TNF IL6 IFNG
35 toxoplasmosis 30.2 TNF IL6 IL5 IL4 IFNG
36 ocular cicatricial pemphigoid 30.2 RNASE3 NGF IL4
37 neurofibromatosis, type ii 30.2 TNF IL6 CXCL8
38 purpura 30.2 TNF IL6 IL4
39 corneal disease 30.2 TNF NGF MMP9 IL6 CXCL8
40 pollen allergy 30.2 RNASE3 IL5 IL3 IL13 ICAM1
41 pertussis 30.1 TNF IL6 CXCL8 CCL11
42 bronchopneumonia 30.1 TNF IL6 CXCL8
43 subacute cutaneous lupus erythematosus 30.1 TRIM21 TNF
44 immune deficiency disease 30.1 TNF IL6 IL4 IL2 IL13 IFNG
45 sarcoidosis 1 30.1 TNF IL2 IL13 IFNG ICAM1
46 systemic autoimmune disease 30.1 MMP9 IL6 IL17A
47 mastocytosis 30.1 IL6 IL4 IL3 IL13
48 haemophilus influenzae 30.1 TNF CXCL8
49 blepharitis 30.1 TNF MUC5AC MUC16 MMP9 IL6 IL4
50 retinal vein occlusion 30.0 TNF IL6 CXCL8

Comorbidity relations with Keratoconjunctivitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Keratoconjunctivitis:



Diseases related to Keratoconjunctivitis

Symptoms & Phenotypes for Keratoconjunctivitis

MGI Mouse Phenotypes related to Keratoconjunctivitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 CCL11 CCL24 ICAM1 IFNG IL13 IL17A
2 homeostasis/metabolism MP:0005376 10.22 ICAM1 IFNG IL13 IL17A IL2 IL4
3 immune system MP:0005387 10.21 CCL11 CCL24 ICAM1 IFNG IL13 IL17A
4 digestive/alimentary MP:0005381 10.2 ICAM1 IFNG IL13 IL17A IL2 IL4
5 integument MP:0010771 10.02 ICAM1 IFNG IL13 IL17A IL4 IL6
6 neoplasm MP:0002006 9.8 ICAM1 IFNG IL2 IL5 IL6 MMP9
7 no phenotypic analysis MP:0003012 9.7 IFNG IL13 IL17A IL2 IL4 NGF
8 respiratory system MP:0005388 9.7 CCL11 CCL24 IFNG IL13 IL17A IL2
9 vision/eye MP:0005391 9.32 CD46 ICAM1 IFNG IL2 IL4 IL6

Drugs & Therapeutics for Keratoconjunctivitis

Drugs for Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 230)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pseudoephedrine Approved Phase 4 90-82-4 7028
2
Ephedrine Approved Phase 4 299-42-3 9294
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
4
Povidone Approved Phase 4 9003-39-8
5
Histamine Approved, Investigational Phase 4 51-45-6 774
6
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
7
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
8
Glycerol Approved, Investigational Phase 4 56-81-5 753
9
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
10
Dipivefrin Approved Phase 4 52365-63-6 3105
11
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
12
Ofloxacin Approved Phase 4 82419-36-1 4583
13
Azithromycin Approved Phase 4 83905-01-5 55185 447043
14
Ethanol Approved Phase 4 64-17-5 702
15
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
16
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
17
Menthol Approved Phase 4 2216-51-5 16666
18
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
21
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
22
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
23
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
24 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
25
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
27
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
28
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
29
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
30 Rebamipide Investigational Phase 4 90098-04-7
31
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
32 Vasoconstrictor Agents Phase 4
33 Nasal Decongestants Phase 4
34 Calciferol Phase 4
35 Cathartics Phase 4
36 Laxatives Phase 4
37 Carboxymethylcellulose Sodium Phase 4
38 Anti-Ulcer Agents Phase 4
39 Antacids Phase 4
40 Plasma Substitutes Phase 4
41 Blood Substitutes Phase 4
42 Anti-Asthmatic Agents Phase 4
43 Respiratory System Agents Phase 4
44 Histamine H1 Antagonists Phase 4
45 Histamine Antagonists Phase 4
46 Isospaglumic acid Phase 4
47
Histamine Phosphate Phase 4 51-74-1 65513
48 Bronchodilator Agents Phase 4
49 Antiviral Agents Phase 4
50 Ganciclovir triphosphate Phase 4

Interventional clinical trials:

(show top 50) (show all 582)
# Name Status NCT ID Phase Drugs
1 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
2 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
3 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
4 A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
5 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
6 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD). Unknown status NCT02992535 Phase 4
7 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
8 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
9 Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy Unknown status NCT01561040 Phase 4
10 A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye Completed NCT02139033 Phase 4 Retaine™
11 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
12 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
13 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
14 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
15 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
16 The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study Completed NCT00809198 Phase 4
17 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
18 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
19 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
20 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
21 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
22 Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients Completed NCT00520260 Phase 4 bromfenac;ketorolac
23 A Randomized, Single-Center, Comparative Study of Rohto Dry-Aid® and Systane® Ultra in the Management of Tear Film Stability and Visual Function in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
24 Evaluation of the Repeated Usage of Systane Ultra Eyedrop Completed NCT01051804 Phase 4
25 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
26 Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
27 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
28 A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine Completed NCT00407043 Phase 4 Lotemax;Restasis
29 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
30 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
31 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
32 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
33 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
34 Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
35 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
36 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
37 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
38 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
39 Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
40 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
41 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
42 A Randomized Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
43 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
44 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
45 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
46 Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients Completed NCT01311609 Phase 4
47 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
48 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
49 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
50 The Comparison of 50 % Concentration Autologous Serum Eye Drops Versus Preservative Free Artificial Eye Drop Plus 0.05 % Cyclosporin Ophthalmic Emulsion in the Treatment of Severe Dry Eye Syndrome: A Randomized Comparative Study Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1

Search NIH Clinical Center for Keratoconjunctivitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Lodoxamide
lodoxamide tromethamine

Cochrane evidence based reviews: keratoconjunctivitis

Genetic Tests for Keratoconjunctivitis

Anatomical Context for Keratoconjunctivitis

MalaCards organs/tissues related to Keratoconjunctivitis:

40
Eye, Testes, T Cells, Thyroid, Salivary Gland, Bone, B Cells

Publications for Keratoconjunctivitis

Articles related to Keratoconjunctivitis:

(show top 50) (show all 4392)
# Title Authors PMID Year
1
Ocular complications of autoimmune polyendocrinopathy syndrome type 1. 54 61
17189144 2006
2
Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. 54 61
10682966 2000
3
Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. 54 61
10606937 2000
4
Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. 54 61
10469030 1999
5
Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. 54 61
10359913 1999
6
Steroid-induced glaucoma and blindness in vernal keratoconjunctivitis. 61
31055451 2020
7
Dupilumab Therapy in a Patient with Atopic Dermatitis and Severe Atopic Keratoconjunctivitis. 61
32031716 2020
8
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies: Erratum. 61
31714407 2020
9
Comment on: "Safety and Efficacy of Supratarsal Triamcinolone for Treatment of Vernal Keratoconjunctivitis in Ireland". 61
31725700 2020
10
Corneoconjunctival transposition for the treatment of deep stromal to full-thickness corneal defects in dogs: A multicentric retrospective study of 100 cases (2012-2018). 61
31950569 2020
11
Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study. 61
31361655 2020
12
Corneal hypoesthesia, aqueous tear deficiency, and neurotrophic keratopathy following micropulse transscleral cyclophotocoagulation in dogs. 61
31464376 2020
13
[Side effects of keratoconjunctivitis sicca treatment]. 61
31407051 2020
14
Copper for the Prevention of Outbreaks of Health Care-Associated Infections in a Long-term Care Facility for Older Adults. 61
30954421 2020
15
Transepithelial Surface Ablation With Mitomycin C for the Treatment of Chronic Central Corneal Scars Following Adenoviral Keratoconjunctivitis. 61
31917852 2020
16
Hand hygiene and instrument sanitization in ophthalmology clinics. 61
31770164 2020
17
Understanding Infection Prevention Practices in Optometry Clinics. 61
31895274 2020
18
Randomised Control Trial Comparing Cypermethrin-Based Preparations in the Prevention of Infectious Bovine Keratoconjunctivitis in Cattle. 61
31978947 2020
19
Finger-Prick Autologous Blood in the Treatment of Persistent Corneal Epithelial Defects. 61
31868852 2019
20
Two cases of epidemic keratoconjunctivitis-associated dacryocystitis. 61
31852315 2019
21
Genomic foundations of evolution and ocular pathogenesis in human adenovirus species D. 61
31769017 2019
22
Mystery eye: Human adenovirus and the enigma of epidemic keratoconjunctivitis. 61
31891773 2019
23
Demographic and clinical profile of microspodial keratitis in North India: an underreported entity. 61
31749531 2019
24
Ocular Co-Morbidities of Atopic Dermatitis. Part I: Associated Ocular Diseases. 61
31359350 2019
25
Air pollution significantly associated with severe ocular allergic inflammatory diseases. 61
31796815 2019
26
[Genetic characteristics of five human adenovirus type 53 strains isolated from Taiyuan city in 2016, China]. 61
31795585 2019
27
A 8-year retrospective clinical analysis of 272 patients of epidemic Keratoconjunctivitis in Beijing, China. 61
31856790 2019
28
Disinfectant potential in inactivation of epidemic keratoconjunctivitis-related adenoviruses by potassium peroxymonosulfate. 61
31813297 2019
29
Assessment of clinical signs associated with adenoviral epidemic keratoconjunctivitis cases in southern Japan between 2011 and 2014. 61
31607514 2019
30
Role of ocular cytology in vernal keratoconjunctivitis. 61
31804769 2019
31
Anthocyanin-Functionalized Contact Lens Sensors for Ocular pH Monitoring. 61
31891056 2019
32
Mycoplasma conjunctivae-Associated Keratoconjunctivitis in Norwegian Muskox (Ovibos moschatus). 61
31833817 2019
33
Comprehensive analysis of hazard of ultraviolet radiation emitted during arc welding of cast iron. 61
31794117 2019
34
Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. 61
31762357 2019
35
Bilateral orbital involvement of IgG4-related disease detected on 18F-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: A Clinical Case Report. 61
31764855 2019
36
Design and Outcomes of a Novel Keratoprosthesis: Addressing Unmet Needs in End-Stage Cicatricial Corneal Blindness. 61
31724985 2019
37
Acremonium and trichosporon fungal keratoconjunctivitis in a Leopard Gecko (Eublepharis macularius). 61
31339654 2019
38
12-Month Results of Cyclosporine A Cationic Emulsion in a Randomized, Study in Patients With Pediatric Vernal Keratoconjunctivitis. 61
31770513 2019
39
Assessment of meibomian gland morphology by noncontact infrared meibography in Shih Tzu dogs with or without keratoconjunctivitis sicca. 61
30715776 2019
40
First report of traumatic scleral rupture after penetrating keratoplasty. 61
31701505 2019
41
The Impact of Bilateral Subepithelial Corneal Infiltrates on Tear Film After Epidemic Keratoconjunctivitis. 61
31794540 2019
42
Swimming Pool-Associated Vittaforma-Like Microsporidia Linked to Microsporidial Keratoconjunctivitis Outbreak, Taiwan. 61
31625849 2019
43
A 2-year randomized blinded controlled trial of a conditionally licensed Moraxella bovoculi vaccine to aid in prevention of infectious bovine keratoconjunctivitis in Angus beef calves. 61
31605550 2019
44
Clinical findings of traumatic proptosis in small-breed dogs and complications associated with globe replacement surgery. 61
31998615 2019
45
Isolation of Intact Eyeball to Obtain Integral Ocular Surface Tissue for Histological Examination and Immunohistochemistry. 61
31680683 2019
46
Pathogenesis and complications of chronic eye rubbing in ocular allergy. 61
31343437 2019
47
Allergic eye disease in children and adolescents seeking eye care in India: Electronic medical records driven big data analytics report II. 61
31476516 2019
48
Gonioscopy-assisted Transluminal Trabeculotomy in a Pediatric Patient With Steroid-induced Glaucoma. 61
31574020 2019
49
Disability Related to Chronic Graft-versus-Host Disease. 61
31669175 2019
50
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies. 61
31306284 2019

Variations for Keratoconjunctivitis

Expression for Keratoconjunctivitis

Search GEO for disease gene expression data for Keratoconjunctivitis.

Pathways for Keratoconjunctivitis

Pathways related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TRIM21 TNF RNASE3 MUC5AC MUC16 MMP9
2
Show member pathways
13.93 TNF NGF IL6 IL5 IL4 IL3
3
Show member pathways
13.8 TNF NGF IL6 IL5 IL4 IL3
4
Show member pathways
13.66 TNF NGF IL6 IL5 IL4 IL3
5
Show member pathways
13.54 TNF NGF IL6 IL5 IL4 IL3
6
Show member pathways
13.45 TRIM21 TNF MMP9 IL6 IL5 IL4
7
Show member pathways
13.44 TNF NGF IL6 IL5 IL4 IL3
8
Show member pathways
13.17 TNF MMP9 IL6 IL2 IFNG CXCL8
9
Show member pathways
13.05 TNF NGF IL6 IL4 IL3 IL2
10 13.01 MMP9 IL6 IL5 IL4 IL3 IL2
11
Show member pathways
12.94 TNF IL6 IL2 IFNG ICAM1 CXCL8
12
Show member pathways
12.77 TNF IL6 IL5 IL4 IL2 IL17A
13
Show member pathways
12.76 TNF NGF IL6 IL3 IL2
14
Show member pathways
12.74 TNF IL6 IL5 IL4 IL2 IL17A
15 12.71 TNF IL4 IL3 IL2 IL17A IFNG
16
Show member pathways
12.66 TNF IL6 IL2 IL17A IFNG
17
Show member pathways
12.65 TNF IL5 IL4 IL3 IL13
18
Show member pathways
12.65 TNF IL4 IL3 IL2 IFNG ICAM1
19
Show member pathways
12.52 IL6 IL5 IL4 IL3 IL2 IL13
20
Show member pathways
12.48 TNF IL6 IL2 CXCL8 CCL24 CCL11
21
Show member pathways
12.47 TNF IL6 IL4 IL2 IFNG ICAM1
22
Show member pathways
12.4 ICAM1 CXCL8 CCL24 CCL11
23 12.39 TNF IL6 IL2 ICAM1
24
Show member pathways
12.35 TNF IL6 IL4 IFNG CXCL8 CCL11
25
Show member pathways
12.35 TNF NGF IL6 IL5 IL4 IL3
26 12.32 MMP9 IL6 IL3 CXCL8
27 12.3 TNF NGF IL6 IL13 CXCL8
28
Show member pathways
12.29 TNF MUC5AC IL6 CXCL8
29 12.26 TNF MMP9 IL6 IFNG
30
Show member pathways
12.22 TNF MMP9 IL6 IL4 IL13 IFNG
31 12.2 TNF IL6 IL5 IL4 IL3 IL2
32
Show member pathways
12.19 TNF IL6 IL2 IL17A IFNG
33 12.19 TNF MMP9 IL6 IL4 IL2 IFNG
34
Show member pathways
12.18 TNF RNASE3 IL6 IL5 IL4 IL3
35 12.17 TNF MMP9 IFNG ICAM1
36 12.1 TNF IL6 IL2 CXCL8
37 12.07 TNF MMP9 IL6 ICAM1
38 12.07 TNF IL6 IL17A IFNG ICAM1 CXCL8
39 12.06 TNF IL6 IL5 IL4 IL3
40 12.04 IL6 IL3 IFNG CXCL8
41 12.03 TNF MMP9 IL6 IL4 IL17A IL13
42
Show member pathways
12.03 TNF MUC5AC MMP9 IL6 IL5 IL4
43 12.02 TNF IL6 IFNG CXCL8
44 12.01 TNF IL6 ICAM1 CXCL8
45 11.99 TNF IL5 IL4 IL2 IL17A IL13
46 11.99 IL6 IL5 IL4 IL2 IL13 IFNG
47 11.97 IL6 IL3 IL2 IFNG
48
Show member pathways
11.97 IL6 IL17A ICAM1 CXCL8
49
Show member pathways
11.96 TNF IL5 IL4 IL3 IL2 IFNG
50 11.87 TNF IL6 IL2 IFNG

GO Terms for Keratoconjunctivitis

Cellular components related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 TNF RNASE3 NGF MUC5AC MUC16 MMP9
2 extracellular space GO:0005615 9.58 TNF RNASE3 NGF MUC5AC MUC16 MMP9

Biological processes related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.97 IL3 IL2 IL17A CCL24
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 TNF ICAM1 CCL24 CCL11
3 positive regulation of gene expression GO:0010628 9.95 TNF NGF IL6 IL4 IL13 IFNG
4 positive regulation of protein phosphorylation GO:0001934 9.94 TNF MMP9 IL2 IFNG
5 cellular response to lipopolysaccharide GO:0071222 9.94 TNF IL6 ICAM1 CXCL8
6 cellular response to tumor necrosis factor GO:0071356 9.9 ICAM1 CXCL8 CCL24 CCL11
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.86 TRIM21 TNF IL6 IL5
8 inflammatory response GO:0006954 9.86 TNF IL6 IL5 IL17A IL13 CXCL8
9 chemokine-mediated signaling pathway GO:0070098 9.84 CXCL8 CCL24 CCL11
10 interferon-gamma-mediated signaling pathway GO:0060333 9.84 TRIM21 IFNG ICAM1
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 TNF IL6 IL13
12 humoral immune response GO:0006959 9.82 TNF IL6 IFNG
13 positive regulation of actin filament polymerization GO:0030838 9.81 ICAM1 CCL24 CCL11
14 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 IL6 IL5 IL3 ICAM1
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.79 TNF IFNG ICAM1
16 monocyte chemotaxis GO:0002548 9.79 IL6 CCL24 CCL11
17 negative regulation of endothelial cell apoptotic process GO:2000352 9.77 IL4 IL13 ICAM1
18 positive regulation of T cell proliferation GO:0042102 9.76 IL6 IL4 IL2 CD46
19 positive regulation of JAK-STAT cascade GO:0046427 9.74 TNF IL6 IL5
20 immune response GO:0006955 9.73 TNF IL6 IL5 IL4 IL3 IL2
21 microglial cell activation GO:0001774 9.72 TNF IL13 IFNG
22 cellular response to interleukin-1 GO:0071347 9.72 IL17A ICAM1 CXCL8 CCL24 CCL11
23 negative regulation of neurogenesis GO:0050768 9.71 TNF IL6 CCL11
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.7 TNF IL6 IL4 IL3 IL2 IL13
25 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF IFNG
26 negative regulation of amyloid-beta clearance GO:1900222 9.68 TNF IFNG
27 regulation of neuroinflammatory response GO:0150077 9.68 MMP9 IL6
28 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 IL4 IL2
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL4 IFNG
30 positive regulation of B cell proliferation GO:0030890 9.67 IL5 IL4 IL2 IL13
31 negative regulation of lipid storage GO:0010888 9.66 TNF IL6
32 positive regulation of osteoclast differentiation GO:0045672 9.65 TNF IL17A IFNG
33 neuroinflammatory response GO:0150076 9.63 IL4 IFNG
34 positive regulation of interleukin-23 production GO:0032747 9.62 IL17A IFNG
35 positive regulation of cellular respiration GO:1901857 9.61 IL4 IFNG
36 positive regulation of immunoglobulin secretion GO:0051024 9.61 IL6 IL5 IL2
37 negative regulation of complement-dependent cytotoxicity GO:1903660 9.58 IL4 IL13
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 TNF IFNG
39 positive regulation of vitamin D biosynthetic process GO:0060557 9.52 TNF IFNG
40 positive regulation of nitrogen compound metabolic process GO:0051173 9.51 TNF IFNG
41 cytokine-mediated signaling pathway GO:0019221 9.4 TNF MMP9 IL6 IL5 IL4 IL3

Molecular functions related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 TRIM21 TNF NGF MUC5AC MUC16 MMP9
2 chemokine activity GO:0008009 9.5 CXCL8 CCL24 CCL11
3 growth factor activity GO:0008083 9.43 NGF IL6 IL5 IL4 IL3 IL2
4 cytokine activity GO:0005125 9.4 TNF IL6 IL5 IL4 IL3 IL2
5 CCR3 chemokine receptor binding GO:0031728 9.16 CCL24 CCL11

Sources for Keratoconjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....